Jpmorgan Chase Bank, N.a.

Insite Vision Corporation

Dey, L.p.

Mylan Pharmaceuticals Inc.

Avalyn Pharma Inc.

Mylan Specialty LP

Dey Pharma, L.p.

Other

Sun Pharmaceutical Industries Limited

Pari Pharma Gmbh

Sun Pharma Global Fze

Stephen Pham

Imtiaz A Chaudry

Partha S Banerjee

Lyle M Bowman

Mark William Surber

Erwin C Si

Kamran Hosseini

Samuel O Akapo

Thomas Gallem

Reynaldo J Quintana

Uwe Hetzer

Roy D Archibald

David Mufson

S Kumar Chandrasekaran

Roy Duane Archibald

The disclosure provides compositions and systems for topical ophthalmic application, which include an aqueous mixture of bromfenac and flowable mucoadhesive polymer, for treating inflammation and inflammatory conditions of the eye.

Non-steroidal anti-inflammatory ophthalmic compositions

Disclosed herein are formulations of nintedanib and salts thereof, indolinone derivative compounds and salts thereof for aerosolization and use of such formulations for the prevention or treatment of various fibrotic, carcinogenic, vascular and viral infectious diseases, including diseases associated with the lung, heart, kidney, liver, eye, central nervous system and surgical sites. Formulations and delivery options described herein allow for efficacious local delivery of nintedanib or a indolinone derivative compound or salt thereof. Methods include inhalation procedures, indications and manufacturing processes for production and use of the compositions described. Also included are methods for identifying compounds and indications that benefit by reformulation and inhalation administration.

Specially formulated compositions of inhaled nintedanib and nintedanib salts

An opening element for opening an ampoule in an aerosol generation device includes a first member which has a conduit extending therethrough for guiding a fluid contained in the ampoule through the first member and a second member which is arranged at least partly inside or on the conduit. Further, an aerosol generation device includes such an opening element.

Opening element for opening an ampoule in an aerosol generation device and aerosol generation device comprising the opening element

Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.

Bronchodilating beta-agonist compositions and methods

Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof, and a steroidal anti-inflammatory agent. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.

Formoterol/steroid bronchodilating compositions and methods of use thereof

Bronchodilating Beta-agonist compositions and methods

An ophthalmically acceptable vehicle includes an aqueous suspension having a first viscosity. The suspension includes about 0.1% to about 6.5% by weight of a carboxyl-containing polymer prepared by polymerizing one or more carboxyl-containing monoethylenically unsaturated monomers and less than about 5% by weight of a cross-linking agent. The polymer has average particle size of not more than about 50 &#x3bc;m in equivalent spherical diameter. The vehicle includes a second polymer that allows the carboxyl-containing polymer to remain suspended. Upon contact with tear fluid, the vehicle gels to a second viscosity which is greater than the first viscosity. A method of administering a medicament to the eye of a subject includes applying a composition that includes this ophthalmically acceptable vehicle and a medicament contained for treatment of a disease or disorder for which ophthalmic delivery is indicated. The medicament is released from the vehicle in a sustained release manner.

Controlled-release ophthalmic vehicles

Bronchodilating &#x3b2;-agonist compositions and methods

The present invention relates to formulations of concentrated azalide antibiotics and methods for making and using them. Specifically, the invention relates to a method of treating an infection comprising administering to a patient in need thereof, an effective amount of a concentrated aqueous azalide antibiotic formulation made according to the method comprising dissolving an azalide antibiotic in an aqueous solution comprising a strong acid. The invention also relates to methods for making concentrated aqueous azalide antibiotic formulations for use in pulmonary infection, a nasopharyngeal infection, an otic infection, an ocular infection, a dermal or a vaginal infection. The invention also relates to concentrated aqueous azalide antibiotic formulations made by dissolving an azalide antibiotic in an aqueous solution comprising a strong acid.

Concentrated aqueous azalide formulations

Growing community of inventors

Sacramento, CA, United States of America

Stephen Pham